다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

ABBV AbbVie Inc

177.85

1.65 (0.94%)

01 1월(1) 2025 - 마감

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/16/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Kevin K Buckbee

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

AbbVie (NYSE:ABBV)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025

AbbVie 차트를 더 보려면 여기를 클릭.

AbbVie (NYSE:ABBV)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025

AbbVie 차트를 더 보려면 여기를 클릭.

AbbVie Inc News

L'atogépant et l'onabotulinumtoxinA d'AbbVie font l'objet de recommandations fortes dans les lignes directrices récemment mises à jour de la Canadian Headache Society portant sur la prévention de la migraine
0년 19월 12일, 2024 (2 주 전) • PR Newswire (Canada)

Form 4 - Statement of changes in beneficial ownership of securities
0년 19월 12일, 2024 (2 주 전) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
0년 17월 12일, 2024 (2 주 전) • Edgar (US Regulatory)

Form 8-K - Current report
0년 14월 12일, 2024 (3 주 전) • Edgar (US Regulatory)

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
0년 13월 12일, 2024 (3 주 전) • PR Newswire (US)

AbbVie Completes Acquisition of Aliada Therapeutics
0년 11월 12일, 2024 (3 주 전) • PR Newswire (US)

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
0년 10월 12일, 2024 (3 주 전) • PR Newswire (US)

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
0년 9월 12일, 2024 (3 주 전) • PR Newswire (US)

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
0년 9월 12일, 2024 (3 주 전) • PR Newswire (US)

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
0년 8월 12일, 2024 (4 주 전) • PR Newswire (US)

AbbVie to Present at Citi's 2024 Global Healthcare Conference
0년 25월 11일, 2024 (1 월 전) • PR Newswire (US)

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
0년 18월 11일, 2024 (1 월 전) • PR Newswire (US)

More AbbVie Inc News Articles

SPDR S&P Global Natural ...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관